

Neuropeptide S receptor in GtoPdb v.2025.3

Girolamo Caló¹, Olivier Civelli², Rainer K. Reinscheid³ and Chiara Ruzza⁴

1. University of Padova, Italy
2. University of California, Irvine, USA
3. University Hospital Jena, Germany
4. University of Ferrara, Italy

Abstract

The neuropeptide S receptor (NPS receptor) responds to the 20 amino-acid peptide neuropeptide S derived from a precursor ([NPS](#), [P0C0P6](#)). NPS activates its receptor at low nanomolar concentrations elevating intracellular cAMP and calcium levels [74]. Currently, some peptidic and small molecule NPS receptor antagonists are available as research tools [30, 82, 9, 62]. No NPS receptor ligands are currently used clinically.

Contents

This is a citation summary for Neuropeptide S receptor in the [Guide to Pharmacology](#) database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [7].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

Neuropeptide S receptor

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=44>

Introduction to Neuropeptide S receptor

<https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=44>

Receptors

NPS receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=302>

References

1. Acevedo N, Säaf A, Söderhäll C, Melén E, Mandelin J, Pietras CO, Ezer S, Karisola P, Vendelin J and Gennäs GB *et al.* (2013) Interaction between retinoid acid receptor-related orphan receptor alpha (RORA) and neuropeptide S receptor 1 (NPSR1) in asthma. *PLoS ONE* **8**: e60111 [PMID:23565190]
2. Adori C, Barde S, Bogdanovic N, Uhlén M, Reinscheid RR, Kovacs GG and Hökfelt T. (2015) Neuropeptide S- and Neuropeptide S receptor-expressing neuron populations in the human pons. *Front Neuroanat* **9**: 126 [PMID:26441556]
3. Allen IC, Pace AJ, Jania LA, Ledford JG, Latour AM, Snouwaert JN, Bernier V, Stocco R, Therien AG and Koller BH. (2006) Expression and function of NPSR1/GPRA in the lung before and after

induction of asthma-like disease. *Am J Physiol Lung Cell Mol Physiol* **291**: L1005-17 [PMID:16829631]

4. Beiderbeck DI, Lukas M and Neumann ID. (2014) Anti-aggressive effects of neuropeptide S independent of anxiolysis in male rats. *Front Behav Neurosci* **8**: 185 [PMID:24910598]
5. Bernier V, Stocco R, Bogusky MJ, Joyce JG, Parachoniak C, Grenier K, Arget M, Mathieu MC, O'Neill GP and Slipetz D *et al.*. (2006) Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I. *J Biol Chem* **281**: 24704-12 [PMID:16790440]
6. Beste C, Konrad C, Uhlmann C, Arolt V, Zwanzger P and Domschke K. (2013) Neuropeptide S receptor (NPSR1) gene variation modulates response inhibition and error monitoring. *Neuroimage* **71**: 1-9 [PMID:23319044]
7. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [PMID:32367113]
8. Bülbül M, Sinen O, Özkan A, Aslan MA and Açar A. (2019) Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats. *Exp Neurol* **317**: 78-86 [PMID:30825442]
9. Camarda V, Rizzi A, Ruzza C, Zucchini S, Marzola G, Marzola E, Guerrini R, Salvadori S, Reinscheid RK and Regoli D *et al.*. (2009) In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. *J Pharmacol Exp Ther* **328**: 549-55 [PMID:18971372]
10. Cannella N, Economidou D, Kallupi M, Stopponi S, Heilig M, Massi M and Ciccocioppo R. (2009) Persistent increase of alcohol-seeking evoked by neuropeptide S: an effect mediated by the hypothalamic hypocretin system. *Neuropsychopharmacology* **34**: 2125-34 [PMID:19322167]
11. Castro AA, Moretti M, Casagrande TS, Martinello C, Petronilho F, Steckert AV, Guerrini R, Calo' G, Dal Pizzol F and Quevedo J *et al.*. (2009) Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam. *Pharmacol Biochem Behav* **91**: 636-42 [PMID:19022279]
12. Chauveau F, Claverie D, Lardant E, Varin C, Hardy E, Walter A, Canini F, Rouach N and Rancillac A. (2020) Neuropeptide S promotes wakefulness through the inhibition of sleep-promoting ventrolateral preoptic nucleus neurons. *Sleep* **43** [PMID:31403694]
13. Clark SD, Duangdao DM, Schulz S, Zhang L, Liu X, Xu YL and Reinscheid RK. (2011) Anatomical characterization of the neuropeptide S system in the mouse brain by in situ hybridization and immunohistochemistry. *J Comp Neurol* **519**: 1867-93 [PMID:21452235]
14. Clark SD, Kenakin TP, Gertz S, Hassler C, Gay EA, Langston TL, Reinscheid RK and Runyon SP. (2017) Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation. *Neuropharmacology* **118**: 69-78 [PMID:28267583]
15. D'Amato M, Bruce S, Bresso F, Zucchelli M, Ezer S, Pulkkinen V, Lindgren C, Astegiano M, Rizzetto M and Gionchetti P *et al.*. (2007) Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. *Gastroenterology* **133**: 808-17 [PMID:17854592]
16. Didonet JJ, Cavalcante JC, Souza Lde S, Costa MS, André E, Soares-Rachetti Vde P, Guerrini R, Calo' G and Gavioli EC. (2014) Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice. *Behav Brain Res* **266**: 29-36 [PMID:24613977]
17. Dine J, Ionescu IA, Avrabos C, Yen YC, Holsboer F, Landgraf R, Schmidt U and Eder M. (2015) Intranasally applied neuropeptide S shifts a high-anxiety electrophysiological endophenotype in the ventral hippocampus towards a "normal"-anxiety one. *PLoS ONE* **10**: e0120272 [PMID:25830625]
18. Domschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P, Pedersen A, Bauer J, Suslow T and Kugel H *et al.*. (2011) Neuropeptide S receptor gene -- converging evidence for a role in panic disorder. *Mol Psychiatry* **16**: 938-48 [PMID:20603625]
19. Donner J, Haapakoski R, Ezer S, Melén E, Pirkola S, Gratacòs M, Zucchelli M, Anedda F, Johansson LE and Söderhäll C *et al.*. (2010) Assessment of the neuropeptide S system in anxiety disorders. *Biol Psychiatry* **68**: 474-83 [PMID:20705147]
20. Duangdao DM, Clark SD, Okamura N and Reinscheid RK. (2009) Behavioral phenotyping of neuropeptide S receptor knockout mice. *Behav Brain Res* **205**: 1-9 [PMID:19646487]
21. Erdmann F, Kügler S, Blaesse P, Lange MD, Skryabin BV, Pape HC and Jüngling K. (2015) Neuronal expression of the human neuropeptide S receptor NPSR1 identifies NPS-induced calcium signaling pathways. *PLoS ONE* **10**: e0117319 [PMID:25714705]
22. Fedeli A, Braconi S, Economidou D, Cannella N, Kallupi M, Guerrini R, Calò G, Cifani C, Massi M and Ciccocioppo R. (2009) The paraventricular nucleus of the hypothalamus is a neuroanatomical substrate for the inhibition of palatable food intake by neuropeptide S. *Eur J Neurosci* **30**: 1594-602 [PMID:19821837]
23. Fendt M, Büchi M, Bürki H, Imobersteg S, Ricoux B, Suply T and Sailer AW. (2011)

- Neuropeptide S receptor deficiency modulates spontaneous locomotor activity and the acoustic startle response. *Behav Brain Res* **217**: 1-9 [PMID:20888368]
24. Filafferro M, Novi C, Ruggieri V, Genedani S, Alboni S, Malagoli D, Caló G, Guerrini R and Vitale G. (2013) Neuropeptide S stimulates human monocyte chemotaxis via NPS receptor activation. *Peptides* **39**: 16-20 [PMID:23142110]
 25. Garau C, Liu X, Calo G, Schulz S and Reinscheid RK. (2022) Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus. *Neuroscience* **496**: 83-95 [PMID:35710064]
 26. Gardella E, Romei C, Cavallero A, Trapella C, Fedele E and Raiteri L. (2013) Neuropeptide S inhibits release of 5-HT and glycine in mouse amygdala and frontal/prefrontal cortex through activation of the neuropeptide S receptor. *Neurochem Int* **62**: 360-6 [PMID:23411412]
 27. Germer J, Kahl E and Fendt M. (2019) Memory generalization after one-trial contextual fear conditioning: Effects of sex and neuropeptide S receptor deficiency. *Behav Brain Res* **361**: 159-166 [PMID:30597251]
 28. Ghazal P, Corsi M, Roth A, Faggioni F, Corti C, Merlo Pick E, Pucciarelli S, Ciccocioppo R and Ubaldi M. (2014) Paradoxical response to the sedative effects of diazepam and alcohol in C57BL/6J mice lacking the neuropeptide S receptor. *Peptides* **61**: 107-13 [PMID:25240770]
 29. Gottlieb DJ, O'Connor GT and Wilk JB. (2007) Genome-wide association of sleep and circadian phenotypes. *BMC Med Genet* **8 Suppl 1**: S9 [PMID:17903308]
 30. Guerrini R, Camarda V, Trapella C, Caló G, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK and Regoli D *et al.*. (2009) Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. *J Med Chem* **52**: 4068-71 [PMID:19473027]
 31. Guerrini R, Salvadori S, Rizzi A, Regoli D and Calo' G. (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. *Med Res Rev* **30**: 751-77 [PMID:19824051]
 32. Gupte J, Cutler G, Chen JL and Tian H. (2004) Elucidation of signaling properties of vasopressin receptor-related receptor 1 by using the chimeric receptor approach. *Proc Natl Acad Sci USA* **101**: 1508-1513 [PMID:14757815]
 33. Han RW, Chang M, Peng YL, Qiao LY, Yin XQ, Li W and Wang R. (2009) Central Neuropeptide S inhibits distal colonic transit through activation of central Neuropeptide S receptor in mice. *Peptides* **30**: 1313-7 [PMID:19540430]
 34. Han RW, Xu HJ, Zhang RS, Wang P, Chang M, Peng YL, Deng KY and Wang R. (2014) Neuropeptide S interacts with the basolateral amygdala noradrenergic system in facilitating object recognition memory consolidation. *Neurobiol Learn Mem* **107**: 32-6 [PMID:24211255]
 35. Han RW, Yin XQ, Chang M, Peng YL, Li W and Wang R. (2009) Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice. *Neurosci Lett* **455**: 74-7 [PMID:19429110]
 36. Han RW, Zhang RS, Xu HJ, Chang M, Peng YL and Wang R. (2013) Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or A β_{1-42} in mice novel object and object location recognition tasks. *Neuropharmacology* **70**: 261-7 [PMID:23454528]
 37. Holanda AD, Asth L, Santos AR, Guerrini R, de P Soares-Rachetti V, Calo' G, André E and Gavioli EC. (2015) Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test. *Life Sci* **120**: 8-12 [PMID:25447449]
 38. Holanda VAD, Oliveira MC, Souza LS, Lobão-Soares B, André E, Da Silva Junior ED, Guerrini R, Calo G, Ruzza C and Gavioli EC. (2019) Dopamine D₁ and D₂ receptors mediate neuropeptide S-induced antinociception in the mouse formalin test. *Eur J Pharmacol* **859**: 172557 [PMID:31326375]
 39. Ionescu IA, Dine J, Yen YC, Buell DR, Herrmann L, Holsboer F, Eder M, Landgraf R and Schmidt U. (2012) Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. *Neuropsychopharmacology* **37**: 1323-37 [PMID:22278093]
 40. Jüngling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD, Okamura N, Duangdao DM, Xu YL and Reinscheid RK *et al.*. (2008) Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. *Neuron* **59**: 298-310 [PMID:18667157]
 41. Kallupi M, Cannella N, Economidou D, Ubaldi M, Ruggeri B, Weiss F, Massi M, Marugan J, Heilig M and Bonnavion P *et al.*. (2010) Neuropeptide S facilitates cue-induced relapse to cocaine seeking through activation of the hypothalamic hypocretin system. *Proc Natl Acad Sci USA* **107**: 19567-72 [PMID:20974945]
 42. Kolodziejczyk MH and Fendt M. (2020) Corticosterone Treatment and Incubation Time After Contextual Fear Conditioning Synergistically Induce Fear Memory Generalization in Neuropeptide S Receptor-Deficient Mice. *Front Neurosci* **14**: 128 [PMID:32231512]
 43. Kumsta R, Chen FS, Pape HC and Heinrichs M. (2013) Neuropeptide S receptor gene is associated with cortisol responses to social stress in humans. *Biol Psychol* **93**: 304-7 [PMID:23466585]

44. Kushikata T, Yoshida H, Kudo M, Salvadori S, Calo G and Hirota K. (2011) The effects of neuropeptide S on general anesthesia in rats. *Anesth Analg* **112**: 845-9 [PMID:21288975]
45. Laas K, Eensoo D, Paaver M, Lesch KP, Reif A and Harro J. (2015) Further evidence for the association of the NPSR1 gene A/T polymorphism (Asn107Ile) with impulsivity and hyperactivity. *J Psychopharmacol (Oxford)* **29**: 878-83 [PMID:25744621]
46. Laas K, Reif A, Kiive E, Domschke K, Lesch KP, Veidebaum T and Harro J. (2014) A functional NPSR1 gene variant and environment shape personality and impulsive action: a longitudinal study. *J Psychopharmacol (Oxford)* **28**: 227-36 [PMID:23325374]
47. Laitinen T, Polvi A, Rydman P, Vendelin J, Pulkkinen V, Salmikangas P, Mäkelä S, Rehn M, Pirskanen A and Rautanen A *et al.*. (2004) Characterization of a common susceptibility locus for asthma-related traits. *Science* **304**: 300-4 [PMID:15073379]
48. Lee MT, Chiu YT, Chiu YC, Hor CC, Lee HJ, Guerrini R, Calo G and Chiou LC. (2020) Neuropeptide S-initiated sequential cascade mediated by OX₁, NK₁, mGlu₅ and CB₁ receptors: a pivotal role in stress-induced analgesia. *J Biomed Sci* **27**: 7 [PMID:31915019]
49. Lennertz L, Franke PE, Grabe HJ, Rampacher F, Schulze-Rauschenbach S, Guttenthaler V, Ruhrmann S, Pukrop R, Klosterkötter J and Falkai P *et al.*. (2013) The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessive-compulsive disorder. *Int J Neuropsychopharmacol* **16**: 1951-8 [PMID:23680103]
50. Lennertz L, Quednow BB, Schuhmacher A, Petrovsky N, Frommann I, Schulze-Rauschenbach S, Landsberg MW, Steinbrecher A, Höfels S and Pukrop R *et al.*. (2012) The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) is associated with schizophrenia and modulates verbal memory and the acoustic startle response. *Int J Neuropsychopharmacol* **15**: 1205-15 [PMID:22078257]
51. Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE and Rosenzweig-Lipson S *et al.*. (2008) Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. *Psychopharmacology (Berl.)* **197**: 601-11 [PMID:18311561]
52. Leonard SK and Ring RH. (2011) Immunohistochemical localization of the neuropeptide S receptor in the rat central nervous system. *Neuroscience* **172**: 153-63 [PMID:20950671]
53. Li W, Chang M, Peng YL, Gao YH, Zhang JN, Han RW and Wang R. (2009) Neuropeptide S produces antinociceptive effects at the supraspinal level in mice. *Regul Pept* **156**: 90-5 [PMID:19345242]
54. Liao Y, Lu B, Ma Q, Wu G, Lai X, Zang J, Shi Y, Liu D, Han F and Zhou N. (2016) Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues. *J Biol Chem* **291**: 7505-16 [PMID:26865629]
55. Liu X, Si W, Garau C, Jüngling K, Pape HC, Schulz S and Reinscheid RK. (2017) Neuropeptide S precursor knockout mice display memory and arousal deficits. *Eur J Neurosci* **46**: 1689-1700 [PMID:28548278]
56. Liu X, Zeng J, Zhou A, Theodorsson E, Fahrenkrug J and Reinscheid RK. (2011) Molecular fingerprint of neuropeptide S-producing neurons in the mouse brain. *J Comp Neurol* **519**: 1847-66 [PMID:21452230]
57. Lukas M and Neumann ID. (2012) Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects. *Neuropharmacology* **62**: 398-405 [PMID:21871467]
58. Medina G, Ji G, Grégoire S and Neugebauer V. (2014) Nasal application of neuropeptide S inhibits arthritis pain-related behaviors through an action in the amygdala. *Mol Pain* **10**: 32 [PMID:24884567]
59. Meis S, Bergado-Acosta JR, Yanagawa Y, Obata K, Stork O and Munsch T. (2008) Identification of a neuropeptide S responsive circuitry shaping amygdala activity via the endopiriform nucleus. *PLoS ONE* **3**: e2695 [PMID:18628994]
60. Melamed JY, Zartman AE, Kett NR, Gotter AL, Uebele VN, Reiss DR, Condra CL, Fandozzi C, Lubbers LS and Rowe BA *et al.*. (2010) Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists. *Bioorg Med Chem Lett* **20**: 4700-3 [PMID:20510609]
61. Okamura N, Garau C, Duangdao DM, Clark SD, Jüngling K, Pape HC and Reinscheid RK. (2011) Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. *Neuropsychopharmacology* **36**: 744-52 [PMID:21150909]
62. Okamura N, Habay SA, Zeng J, Chamberlin AR and Reinscheid RK. (2008) Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. *J Pharmacol Exp Ther* **325**: 893-901 [PMID:18337476]
63. Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S and Reinscheid RK. (2007) Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. *Prog Neuropsychopharmacol Biol Psychiatry* **31**: 1444-8 [PMID:17669576]

64. Okazaki Y, Furuno M, Kasukawa T, Adachi J, Bono H, Kondo S, Nikaido I, Osato N, Saito R and Suzuki H *et al.*. (2002) Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. *Nature* **420**: 563-73 [PMID:12466851]
65. Pañeda C, Huitron-Resendiz S, Frago LM, Chowen JA, Picetti R, de Lecea L and Roberts AJ. (2009) Neuropeptide S reinstates cocaine-seeking behavior and increases locomotor activity through corticotropin-releasing factor receptor 1 in mice. *J Neurosci* **29**: 4155-61 [PMID:19339610]
66. Peng YL, Han RW, Chang M, Zhang L, Zhang RS, Li W, Han YF and Wang R. (2010) Central Neuropeptide S inhibits food intake in mice through activation of Neuropeptide S receptor. *Peptides* **31**: 2259-63 [PMID:20800637]
67. Peng YL, Zhang JN, Chang M, Li W, Han RW and Wang R. (2010) Effects of central neuropeptide S in the mouse formalin test. *Peptides* **31**: 1878-83 [PMID:20603169]
68. Pulga A, Ruzza C, Rizzi A, Guerrini R and Calo G. (2012) Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. *Eur J Neurosci* **36**: 3531-7 [PMID:22928868]
69. Pulkkinen V, Ezer S, Sundman L, Hagström J, Remes S, Söderhäll C, Greco D, Dario G, Haglund C and Kere J *et al.*. (2014) Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors. *Virchows Arch* **465**: 173-83 [PMID:24915894]
70. Pulkkinen V, Majuri ML, Wang G, Holopainen P, Obase Y, Vendelin J, Wolff H, Rytälä P, Laitinen LA and Haahtela T *et al.*. (2006) Neuropeptide S and G protein-coupled receptor 154 modulate macrophage immune responses. *Hum Mol Genet* **15**: 1667-79 [PMID:16600990]
71. Raczka KA, Gartmann N, Mechias ML, Reif A, Büchel C, Deckert J and Kalisch R. (2010) A neuropeptide S receptor variant associated with overinterpretation of fear reactions: a potential neurogenetic basis for catastrophizing. *Mol Psychiatry* **15**: 1045, 1067-74 [PMID:20628342]
72. Raiteri L, Luccini E, Romei C, Salvadori S and Calò G. (2009) Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. *Br J Pharmacol* **157**: 474-81 [PMID:19371348]
73. Reinscheid RK. (2007) Phylogenetic appearance of neuropeptide S precursor proteins in tetrapods. *Peptides* **28**: 830-7 [PMID:17293003]
74. Reinscheid RK, Xu YL, Okamura N, Zeng J, Chung S, Pai R, Wang Z and Civelli O. (2005) Pharmacological characterization of human and murine neuropeptide s receptor variants. *J Pharmacol Exp Ther* **315**: 1338-45 [PMID:16144971]
75. Ren W, Kiritoshi T, Grégoire S, Ji G, Guerrini R, Calo G and Neugebauer V. (2013) Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors. *J Neurophysiol* **110**: 1765-81 [PMID:23883857]
76. Rizzi A, Vergura R, Marzola G, Ruzza C, Guerrini R, Salvadori S, Regoli D and Calo G. (2008) Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. *Br J Pharmacol* **154**: 471-9 [PMID:18376418]
77. Roncàcè V, Polli FS, Zojicic M and Kohlmeier KA. (2017) Neuropeptide S (NPS) is a neuropeptide with cellular actions in arousal and anxiety-related nuclei: Functional implications for effects of NPS on wakefulness and mood. *Neuropharmacology* **126**: 292-317 [PMID:28655610]
78. Ruland T, Domschke K, Schütte V, Zavorotnyy M, Kugel H, Notzon S, Vennwald N, Ohrmann P, Arolt V and Pfeleiderer B *et al.*. (2015) Neuropeptide S receptor gene variation modulates anterior cingulate cortex Glx levels during CCK-4 induced panic. *Eur Neuropsychopharmacol* **25**: 1677-82 [PMID:26235955]
79. Ruzza C, Asth L, Guerrini R, Trapella C and Gavioli EC. (2015) Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor. *Neuropharmacology* **97**: 1-6 [PMID:25979487]
80. Ruzza C, Ferrari F, Guerrini R, Marzola E, Preti D, Reinscheid RK and Calo G. (2018) Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies. *Pharmacol Res Perspect* **6**: e00445 [PMID:30534379]
81. Ruzza C, Pulga A, Rizzi A, Marzola G, Guerrini R and Calo' G. (2012) Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor. *Neuropharmacology* **62**: 1999-2009 [PMID:22248636]
82. Ruzza C, Rizzi A, Camarda V, Pulga A, Marzola G, Filaferro M, Novi C, Ruggieri V, Marzola E and Vitale G *et al.*. (2012) [tBu-D-Gly⁵]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies. *Peptides* **34**: 404-11 [PMID:22342393]
83. Ruzza C, Rizzi A, Malfacini D, Pulga A, Pacifico S, Salvadori S, Trapella C, Reinscheid RK, Calo G and Guerrini R. (2015) In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranch derivative. *Pharmacol Res Perspect* **3**: e00108 [PMID:25692025]
84. Ruzza C, Rizzi A, Trapella C, Pela' M, Camarda V, Ruggieri V, Filaferro M, Cifani C, Reinscheid RK and Vitale G *et al.*. (2010) Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. *Peptides* **31**: 915-25 [PMID:20172007]
85. Sartori SB, Maurer V, Murphy C, Schmuckermair C, Muigg P, Neumann ID, Whittle N and

- Singewald N. (2016) Combined Neuropeptide S and D-Cycloserine Augmentation Prevents the Return of Fear in Extinction-Impaired Rodents: Advantage of Dual versus Single Drug Approaches. *Int J Neuropsychopharmacol* **19** [PMID:26625894]
86. Sato and Suli *et al.*. (2002) Novel G protein-coupled receptor protein and DNA thereof. Patent number: [WO0231145](#). Assignee: Takeda. Priority date: 13/10/2000. Publication date: 01/01/2002.
 87. Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katirae L, Skaug J and Khaja R *et al.*. (2003) Human chromosome 7: DNA sequence and biology. *Science* **300**: 767-72 [PMID:12690205]
 88. Schmoutz CD, Zhang Y, Runyon SP and Goeders NE. (2012) Antagonism of the neuropeptide S receptor with RTI-118 decreases cocaine self-administration and cocaine-seeking behavior in rats. *Pharmacol Biochem Behav* **103**: 332-7 [PMID:22982682]
 89. Shao YF, Wang C, Xie JF, Kong XP, Xin L, Dong CY, Li J, Ren WT and Hou YP. (2016) Neuropeptide S ameliorates olfactory spatial memory impairment induced by scopolamine and MK801 through activation of cognate receptor-expressing neurons in the subiculum complex. *Brain Struct Funct* **221**: 3327-36 [PMID:26323488]
 90. Shao YF, Zhao P, Dong CY, Li J, Kong XP, Wang HL, Dai LR and Hou YP. (2013) Neuropeptide S facilitates mice olfactory function through activation of cognate receptor-expressing neurons in the olfactory cortex. *PLoS ONE* **8**: e62089 [PMID:23614017]
 91. Si W, Liu X, Pape HC and Reinscheid RK. (2021) Neuropeptide S-Mediated Modulation of Prepulse Inhibition Depends on Age, Gender, Stimulus-Timing, and Attention. *Pharmaceuticals (Basel)* **14** [PMID:34065431]
 92. Sinen O, Bülbül M, Derin N, Ozkan A, Akcay G, Aslan MA and Agar A. (2021) The effect of chronic neuropeptide-S treatment on non-motor parameters in experimental model of Parkinson's disease. *Int J Neurosci* **131**: 765-774 [PMID:32441169]
 93. Smith KL, Patterson M, Dhillo WS, Patel SR, Semjonous NM, Gardiner JV, Ghatei MA and Bloom SR. (2006) Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. *Endocrinology* **147**: 3510-8 [PMID:16574794]
 94. Spada J, Sander C, Burkhardt R, Häntzsch M, Mergl R, Scholz M, Hegerl U and Hensch T. (2014) Genetic association of objective sleep phenotypes with a functional polymorphism in the neuropeptide S receptor gene. *PLoS ONE* **9**: e98789 [PMID:24896296]
 95. Tancredi T, Guerrini R, Marzola E, Trapella C, Calo G, Regoli D, Reinscheid RK, Camarda V, Salvadori S and Temussi PA. (2007) Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor. *J Med Chem* **50**: 4501-8 [PMID:17696420]
 96. Tapmeier TT, Rahmioglu N, Lin J, De Leo B, Obendorf M, Raveendran M, Fischer OM, Bafligil C, Guo M and Harris RA *et al.*. (2021) Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis. *Sci Transl Med* **13** [PMID:34433639]
 97. Thorsell A, Tapocik JD, Liu K, Zook M, Bell L, Flanagan M, Patnaik S, Marugan J, Damadzic R and Dehdashti SJ *et al.*. (2013) A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats. *J Neurosci* **33**: 10132-42 [PMID:23761908]
 98. Tillmann S, Skibdal HE, Christiansen SH, Göttsche CR, Hassan M, Mathé AA, Wegener G and Woldbye DPD. (2019) Sustained overexpression of neuropeptide S in the amygdala reduces anxiety-like behavior in rats. *Behav Brain Res* **367**: 28-34 [PMID:30914309]
 99. Trotter BW, Nanda KK, Manley PJ, Uebele VN, Condra CL, Gotter AL, Menzel K, Henault M, Stocco R and Renger JJ *et al.*. (2010) Tricyclic imidazole antagonists of the Neuropeptide S Receptor. *Bioorg Med Chem Lett* **20**: 4704-8 [PMID:20615693]
 100. Vendelin J, Pulkkinen V, Rehn M, Pirskanen A, Räisänen-Sokolowski A, Laitinen A, Laitinen LA, Kere J and Laitinen T. (2005) Characterization of GPRA, a novel G protein-coupled receptor related to asthma. *Am J Respir Cell Mol Biol* **33**: 262-70 [PMID:15947423]
 101. Vitale G, Filafferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A, Guerrini R and Calò G. (2008) Anxiolytic-like effect of neuropeptide S in the rat defensive burying. *Peptides* **29**: 2286-91 [PMID:18793688]
 102. Wan Saudi WS, Halim MA, Rudholm-Feldreich T, Gillberg L, Rosenqvist E, Tengholm A, Sundbom M, Karlbom U, Näslund E and Webb DL *et al.*. (2015) Neuropeptide S inhibits gastrointestinal motility and increases mucosal permeability through nitric oxide. *Am J Physiol Gastrointest Liver Physiol* **309**: G625-34 [PMID:26206857]
 103. Xing L, Shi G, Mostovoy Y, Gentry NW, Fan Z, McMahon TB, Kwok PY, Jones CR, Ptáček LJ and Fu YH. (2019) Mutant neuropeptide S receptor reduces sleep duration with preserved memory consolidation. *Sci Transl Med* **11** [PMID:31619542]
 104. Xing L, Zou X, Yin C, Webb JM, Shi G, Ptáček LJ and Fu YH. (2024) Diverse roles of pontine NPS-expressing neurons in sleep regulation. *Proc Natl Acad Sci U S A* **121**: e2320276121 [PMID:38381789]
 105. Xu YL, Gall CM, Jackson VR, Civelli O and Reinscheid RK. (2007) Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the

- rat brain. *J Comp Neurol* **500**: 84-102 [PMID:17099900]
106. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK and Henriksen SJ *et al.*. (2004) Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. *Neuron* **43**: 487-97 [PMID:15312648]
 107. Yao Y, Su J, Yang G, Zhang G, Lei Z, Zhang F, Li X, Kou R, Liu Y and Liu J. (2011) Effects of neuropeptide S on the proliferation of splenic lymphocytes, phagocytosis, and proinflammatory cytokine production of pulmonary alveolar macrophages in the pig. *Peptides* **32**: 118-24 [PMID:20933561]
 108. Zhang S, Jin X, You Z, Wang S, Lim G, Yang J, McCabe M, Li N, Marota J and Chen L *et al.*. (2014) Persistent nociception induces anxiety-like behavior in rodents: role of endogenous neuropeptide S. *Pain* **155**: 1504-15 [PMID:24793908]
 109. Zhang Y, Gilmour BP, Navarro HA and Runyon SP. (2008) Identifying structural features on 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones critical for Neuropeptide S antagonist activity. *Bioorg Med Chem Lett* **18**: 4064-7 [PMID:18555684]
 110. Zhao P, Qian X, Nie Y, Sun N, Wang Z, Wu J, Wei C, Ma R, Wang Z and Chai G *et al.*. (2019) Neuropeptide S Ameliorates Cognitive Impairment of APP/PS1 Transgenic Mice by Promoting Synaptic Plasticity and Reducing A β Deposition. *Front Behav Neurosci* **13**: 138 [PMID:31293402]
 111. Zhu H, Mingler MK, McBride ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Williams MT, Vorhees CV and Rothenberg ME. (2010) Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. *Psychoneuroendocrinology* **35**: 1119-32 [PMID:20171785]